DLB subjects with low CSF tau who derive their disease primarily from α-synuclein therefore have worse electrophysiologic disturbances compared to patients whose disease may be attributed to higher co-morbid AD pathology (high CSF Tau). The gene discussed is MAPT; the disease is Lewy body dementia.